{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:29:59Z","timestamp":1790022599035,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>NUT carcinoma (NC), previously known as NUT midline carcinoma, is a rare and very aggressive cancer that occurs in both children and adults. NC is largely chemoresistant, with an overall survival of less than 7\u2009months. Because the carcinoma is not restricted to a particular organ, diagnosis is often a challenge. In the absence of a clearly determined incidence for NC, we sought to study the diagnosis of patients in a well-defined population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We systematically reviewed records of all patients that presented to the Oncology Department of the Princess Margaret Hospital for Children from 1989 to 2014. This institution in the geographically isolated state of Western Australia has a catchment population of around 2 million. We then identified all high grade undifferentiated sarcomas or carcinomas in the 0\u201316\u2009year age group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Over 26\u2009years, we found 14 patients of 16\u2009years or younger with undifferentiated malignant tumors. Of these, five tumors were positive by immunohistochemistry for the NUT\/NUTM1 (Nuclear Protein in Testis) protein and\/or the translocation t(15;19). Three patients presented with thoracic tumors, one with a para-spinal tumor, and one had an upper airway nasopharyngeal carcinoma. In all five cases, there was an initial response to therapy and then progression. This 26-year survey was conducted in a geographically isolated state with a well-defined population, and we determined an estimated incidence of NC of around 0.41 per million child years (0\u201316\u2009yrs. of age) at risk. From three patients it was feasible to derive cell lines for further genetic analyses and drug screening.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>For the first time, the incidence of NC could be determined in a well-defined geographic area. The calculated rate of NC incidence is consistent with a history of under-recognition for this malignancy. These findings indicate that improved diagnostic detection of NC would enable better management and counselling of patients. Our findings emphasize the heterogeneity of NC, and they highlight the need to develop personalised therapy options, and to consider a diagnosis of NC in undifferentiated malignant tumors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08432-0","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T16:02:22Z","timestamp":1624809742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Incidence of NUT carcinoma in Western Australia from 1989 to 2014: a review of pediatric and adolescent cases from Perth Children\u2019s Hospital"],"prefix":"10.1186","volume":"21","author":[{"given":"Tina","family":"Carter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Murch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Beesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"de Klerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula R.","family":"Kees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,27]]},"reference":[{"issue":"11","key":"8432_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/pin.12727","volume":"68","author":"CA French","year":"2018","unstructured":"French CA. NUT carcinoma: Clinicopathologic features, pathogenesis, and treatment. Pathol Int. 2018;68(11):583\u201395. https:\/\/doi.org\/10.1111\/pin.12727.","journal-title":"Pathol Int"},{"key":"8432_CR2","first-page":"1018439","volume":"2019","author":"QW Huang","year":"2019","unstructured":"Huang QW, He LJ, Zheng S, Liu T, Peng BN. An overview of molecular mechanism, Clinicopathological factors, and treatment in NUT carcinoma. Biomed Res Int. 2019;2019:1018439.","journal-title":"Biomed Res Int"},{"issue":"4","key":"8432_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/00043426-199124000-00011","volume":"13","author":"UR Kees","year":"1991","unstructured":"Kees UR, Mulcahy MT, Willoughby ML. Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). Am J Pediatr Hematol Oncol. 1991;13(4):459\u201364. https:\/\/doi.org\/10.1097\/00043426-199124000-00011.","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"12","key":"8432_CR4","first-page":"3327","volume":"51","author":"I Kubonishi","year":"1991","unstructured":"Kubonishi I, Takehara N, Iwata J, Sonobe H, Ohtsuki Y, Abe T, et al. Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res. 1991;51(12):3327\u20138.","journal-title":"Cancer Res"},{"issue":"14","key":"8432_CR5","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1200\/JCO.2013.51.1741","volume":"34","author":"Y Gokmen-Polar","year":"2016","unstructured":"Gokmen-Polar Y, Kesler K, Loehrer PJ Sr, Badve S. NUT midline carcinoma masquerading as a Thymic carcinoma. J Clin Oncol. 2016;34(14):e126\u20139. https:\/\/doi.org\/10.1200\/JCO.2013.51.1741.","journal-title":"J Clin Oncol"},{"key":"8432_CR6","doi-asserted-by":"publisher","unstructured":"Lemelle L, Pierron G, Freneaux P, Huybrechts S, Spiegel A, Plantaz D, et al. NUT carcinoma in children and adults: A multicenter retrospective study. Pediatr Blood Cancer. 2017;64(12).\u00a0https:\/\/doi.org\/10.1002\/pbc.26693.","DOI":"10.1002\/pbc.26693"},{"issue":"39","key":"8432_CR7","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1038\/onc.2012.487","volume":"32","author":"K Thompson-Wicking","year":"2013","unstructured":"Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E, et al. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma. Oncogene. 2013;32(39):4664\u201374. https:\/\/doi.org\/10.1038\/onc.2012.487.","journal-title":"Oncogene"},{"issue":"5","key":"8432_CR8","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/bjc.2014.54","volume":"110","author":"AH Beesley","year":"2014","unstructured":"Beesley AH, Stirnweiss A, Ferrari E, Endersby R, Howlett M, Failes TW, et al. Comparative drug screening in NUT midline carcinoma. Br J Cancer. 2014;110(5):1189\u201398. https:\/\/doi.org\/10.1038\/bjc.2014.54.","journal-title":"Br J Cancer"},{"issue":"11","key":"8432_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.33","volume":"4","author":"A Stirnweiss","year":"2015","unstructured":"Stirnweiss A, McCarthy K, Oommen J, Crook ML, Hardy K, Kees UR, et al. A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma. Oncogenesis. 2015;4(11):e174. https:\/\/doi.org\/10.1038\/oncsis.2015.33.","journal-title":"Oncogenesis"},{"issue":"6","key":"8432_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41379-019-0206-z","volume":"32","author":"TM Stevens","year":"2019","unstructured":"Stevens TM, Morlote D, Xiu J, Swensen J, Brandwein-Weber M, Miettinen MM, et al. NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum. Mod Pathol. 2019;32(6):764\u201373. https:\/\/doi.org\/10.1038\/s41379-019-0206-z.","journal-title":"Mod Pathol"},{"issue":"15","key":"8432_CR11","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","volume":"27","author":"CA French","year":"2008","unstructured":"French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME, et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene. 2008;27(15):2237\u201342. https:\/\/doi.org\/10.1038\/sj.onc.1210852.","journal-title":"Oncogene"},{"issue":"8","key":"8432_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/2159-8290.CD-14-0014","volume":"4","author":"CA French","year":"2014","unstructured":"French CA, Rahman S, Walsh EM, Kuhnle S, Grayson AR, Lemieux ME, et al. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism. Cancer Discovery. 2014;4(8):928\u201341. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0014.","journal-title":"Cancer Discovery"},{"issue":"1","key":"8432_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-pathol-011811-132438","volume":"7","author":"CA French","year":"2012","unstructured":"French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol. 2012;7(1):247\u201365. https:\/\/doi.org\/10.1146\/annurev-pathol-011811-132438.","journal-title":"Annu Rev Pathol"},{"issue":"7","key":"8432_CR14","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-10-3513","volume":"71","author":"BE Schwartz","year":"2011","unstructured":"Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011;71(7):2686\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3513.","journal-title":"Cancer Res"},{"issue":"17","key":"8432_CR15","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1038\/emboj.2010.176","volume":"29","author":"N Reynoird","year":"2010","unstructured":"Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C, et al. Oncogenesis by sequestration of CBP\/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010;29(17):2943\u201352. https:\/\/doi.org\/10.1038\/emboj.2010.176.","journal-title":"EMBO J"},{"issue":"14","key":"8432_CR16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1101\/gad.267583.115","volume":"29","author":"AA Alekseyenko","year":"2015","unstructured":"Alekseyenko AA, Walsh EM, Wang X, Grayson AR, Hsi PT, Kharchenko PV, et al. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes Dev. 2015;29(14):1507\u201323. https:\/\/doi.org\/10.1101\/gad.267583.115.","journal-title":"Genes Dev"},{"issue":"6","key":"8432_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2350\/09-10-0727-CR.1","volume":"13","author":"BM Shehata","year":"2010","unstructured":"Shehata BM, Steelman CK, Abramowsky CR, Olson TA, French CA, Saxe DF, et al. NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic\/hepatic primary. Pediatr Dev Pathol. 2010;13(6):481\u20135. https:\/\/doi.org\/10.2350\/09-10-0727-CR.1.","journal-title":"Pediatr Dev Pathol"},{"issue":"20","key":"8432_CR18","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1158\/1078-0432.CCR-12-1153","volume":"18","author":"DE Bauer","year":"2012","unstructured":"Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Luer SC, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18(20):5773\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1153.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8432_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00405-018-4882-y","volume":"275","author":"P Giridhar","year":"2018","unstructured":"Giridhar P, Mallick S, Kashyap L, Rath GK. Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases. Eur Arch Otorhinolaryngol. 2018;275(3):815\u201321. https:\/\/doi.org\/10.1007\/s00405-018-4882-y.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"7","key":"8432_CR20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/pbc.20755","volume":"49","author":"F Mertens","year":"2007","unstructured":"Mertens F, Wiebe T, Adlercreutz C, Mandahl N, French CA. Successful treatment of a child with t(15;19)-positive tumor. Pediatr Blood Cancer. 2007;49(7):1015\u20137. https:\/\/doi.org\/10.1002\/pbc.20755.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"8432_CR21","doi-asserted-by":"publisher","first-page":"e26946","DOI":"10.1002\/pbc.26946","volume":"65","author":"L Vorstenbosch","year":"2018","unstructured":"Vorstenbosch L, Mavinkurve-Groothuis AMC, van den Broek G, Flucke U, Janssens GO. Long-term survival after relapsed NUT carcinoma of the larynx. Pediatr Blood Cancer. 2018;65(5):e26946. https:\/\/doi.org\/10.1002\/pbc.26946.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"8432_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/PAT.0000000000000208","volume":"47","author":"JF Iacobelli","year":"2015","unstructured":"Iacobelli JF, Charles AK, Crook M, Stewart CJ. NUT protein immunoreactivity in ovarian germ cell tumours. Pathology. 2015;47(2):118\u201322. https:\/\/doi.org\/10.1097\/PAT.0000000000000208.","journal-title":"Pathology"},{"issue":"5","key":"8432_CR23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jcp.50.5.422","volume":"50","author":"JH Williams","year":"1997","unstructured":"Williams JH, Mepham BL, Wright DH. Tissue preparation for immunocytochemistry. J Clin Pathol. 1997;50(5):422\u20138. https:\/\/doi.org\/10.1136\/jcp.50.5.422.","journal-title":"J Clin Pathol"},{"key":"8432_CR24","unstructured":"Statistics ABo: 3101.0 - Australian Demographic Statistics, Mar 2015. In., vol. Tables 2002 to 2017 and Past-Releases, 24\/09\/15 edn. http:\/\/www.abs.gov.au: Australian Bureau of Statistics; 2015."},{"issue":"68","key":"8432_CR25","doi-asserted-by":"publisher","first-page":"112313","DOI":"10.18632\/oncotarget.22862","volume":"8","author":"A Stirnweiss","year":"2017","unstructured":"Stirnweiss A, Oommen J, Kotecha RS, Kees UR, Beesley AH. Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. Oncotarget. 2017;8(68):112313\u201329. https:\/\/doi.org\/10.18632\/oncotarget.22862.","journal-title":"Oncotarget"},{"issue":"9","key":"8432_CR26","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/gcc.3","volume":"57","author":"IM Schaefer","year":"2018","unstructured":"Schaefer IM, Dal Cin P, Landry LM, Fletcher CDM, Hanna GJ, French CA. CIC-NUTM1 fusion: a case which expands the spectrum of NUT-rearranged epithelioid malignancies. Genes Chromosom Cancer. 2018;57(9):446\u201351. https:\/\/doi.org\/10.1002\/gcc.3.","journal-title":"Genes Chromosom Cancer"},{"issue":"2","key":"8432_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/PAS.0000000000001187","volume":"43","author":"F Le Loarer","year":"2019","unstructured":"Le Loarer F, Pissaloux D, Watson S, Godfraind C, Galmiche-Rolland L, Silva K, et al. Clinicopathologic features of CIC-NUTM1 sarcomas, a new molecular variant of the family of CIC-fused sarcomas. Am J Surg Pathol. 2019;43(2):268\u201376. https:\/\/doi.org\/10.1097\/PAS.0000000000001187.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"8432_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/1066896912451651","volume":"21","author":"W Fang","year":"2013","unstructured":"Fang W, French CA, Cameron MJ, Han Y, Liu H. Clinicopathological significance of NUT rearrangements in poorly differentiated malignant tumors of the upper respiratory tract. Int J Surg Pathol. 2013;21(2):102\u201310. https:\/\/doi.org\/10.1177\/1066896912451651.","journal-title":"Int J Surg Pathol"},{"issue":"6","key":"8432_CR29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/PAS.0b013e31815a3900","volume":"32","author":"EB Stelow","year":"2008","unstructured":"Stelow EB, Bellizzi AM, Taneja K, Mills SE, Legallo RD, Kutok JL, et al. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol. 2008;32(6):828\u201334. https:\/\/doi.org\/10.1097\/PAS.0b013e31815a3900.","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"8432_CR30","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/cncr.26528","volume":"118","author":"M Casanova","year":"2012","unstructured":"Casanova M, Bisogno G, Gandola L, Cecchetto G, Di Cataldo A, Basso E, et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian rare tumors in pediatric age (TREP) project. Cancer. 2012;118(10):2718\u201325. https:\/\/doi.org\/10.1002\/cncr.26528.","journal-title":"Cancer"},{"issue":"11","key":"8432_CR31","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1097\/PAS.0b013e3181706252","volume":"32","author":"I Weinreb","year":"2008","unstructured":"Weinreb I, Goldstein D, Perez-Ordonez B. Primary extraskeletal Ewing family tumor with complex epithelial differentiation: a unique case arising in the lateral neck presenting with Horner syndrome. Am J Surg Pathol. 2008;32(11):1742\u20138. https:\/\/doi.org\/10.1097\/PAS.0b013e3181706252.","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"8432_CR32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/modpathol.2008.86","volume":"21","author":"A Bahrami","year":"2008","unstructured":"Bahrami A, Gown AM, Baird GS, Hicks MJ, Folpe AL. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. Mod Pathol. 2008;21(7):795\u2013806. https:\/\/doi.org\/10.1038\/modpathol.2008.86.","journal-title":"Mod Pathol"},{"issue":"5","key":"8432_CR33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","volume":"6","author":"A Stathis","year":"2016","unstructured":"Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte RT, et al. Clinical response of carcinomas harboring the BRD4-NUT Oncoprotein to the targeted Bromodomain inhibitor OTX015\/MK-8628. Cancer Discovery. 2016;6(5):492\u2013500. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1335.","journal-title":"Cancer Discovery"},{"issue":"7327","key":"8432_CR34","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067\u201373. https:\/\/doi.org\/10.1038\/nature09504.","journal-title":"Nature"},{"issue":"30","key":"8432_CR35","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1200\/JCO.2018.78.8695","volume":"36","author":"P Filippakopoulos","year":"2018","unstructured":"Filippakopoulos P. What is the BET on solid tumors? J Clin Oncol. 2018;36(30):3040\u20132. https:\/\/doi.org\/10.1200\/JCO.2018.78.8695.","journal-title":"J Clin Oncol"},{"issue":"30","key":"8432_CR36","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","volume":"36","author":"J Lewin","year":"2018","unstructured":"Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, et al. Phase Ib trial with Birabresib, a small-molecule inhibitor of Bromodomain and Extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36(30):3007\u201314. https:\/\/doi.org\/10.1200\/JCO.2018.78.2292.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8432_CR37","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2018-0115","volume":"5","author":"A Alqahtani","year":"2019","unstructured":"Alqahtani A, Choucair K, Ashraf M, Hammouda DM, Alloghbi A, Khan T, et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019;5(3):FSO372. https:\/\/doi.org\/10.4155\/fsoa-2018-0115.","journal-title":"Future Sci OA"},{"issue":"17\u201318","key":"8432_CR38","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1101\/gad.315648.118","volume":"32","author":"S Liao","year":"2018","unstructured":"Liao S, Maertens O, Cichowski K, Elledge SJ. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4\/6is. Genes Dev. 2018;32(17\u201318):1188\u2013200. https:\/\/doi.org\/10.1101\/gad.315648.118.","journal-title":"Genes Dev"},{"issue":"12","key":"8432_CR39","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1016\/j.celrep.2017.08.082","volume":"20","author":"J Bragelmann","year":"2017","unstructured":"Bragelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Bohm S, et al. Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma. Cell Rep. 2017;20(12):2833\u201345. https:\/\/doi.org\/10.1016\/j.celrep.2017.08.082.","journal-title":"Cell Rep"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08432-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08432-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08432-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T16:03:07Z","timestamp":1624809787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08432-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,27]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8432"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08432-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,27]]},"assertion":[{"value":"6 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was obtained under Reference Number 90EP from the Human Research Ethics Committee of the Princess Margaret Hospital for Children, and no further administrative permissions were required to access the raw data. Consent to participate was given by patients or guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent to participate included permission to access specimens and clinical details, and to publish findings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"740"}}